SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 22, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 15, 2026

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗

Get insights into the top gainers and losers of Monday's pre-market session. ↗

September 14, 2026

Via Chartmill

January 09, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 08, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 01, 2026

SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares are pushing higher Friday morning, extending Thursday’s strong rally.

SELLAS Stock Hits New Highs: What's Happening Today? ↗

June 26, 2026

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 13, 2026

Via Chartmill

These stocks are moving in today's after hours session ↗

May 12, 2026

Via Chartmill

SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum ↗

March 18, 2026

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival events recorded.

The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups.

SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial ↗

March 12, 2026

SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail ↗

March 09, 2026

Shkreli argued that the company lacks a clear mechanism of action and strong clinical data.

Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗

March 09, 2026

Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon.

SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout ↗

Topics ETFs Government Stocks

March 09, 2026

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout ↗

March 06, 2026

The stock's recent surge has been driven by anticipation around the late-stage Regal trial evaluating its leukemia therapy Galinpepimut-S (GPS).

SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout ↗

March 05, 2026

Short interest has risen about 15% since the December update on the Phase 3 Regal trial.

SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside ↗

March 04, 2026

The rally comes ahead of results from the Phase 3 Regal trial testing Galinpepimut-S (GPS) as a maintenance treatment for AML patients.

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage...

SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest? ↗

February 27, 2026

Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% ↗

Topics Death

February 23, 2026

According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours.

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗

Topics Regulatory Compliance

January 14, 2026

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

January 08, 2026

From Equity Insider

Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗

January 06, 2026

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 06, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today ↗

January 06, 2026

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B ↗

Topics Artificial Intelligence ETFs Stocks

January 05, 2026

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the...

Topics Death

Why Is SLS Stock Drawing Significant Investor Attention Today? ↗

December 31, 2025

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Death

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study ↗

December 29, 2025

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover.

Topics Death

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About? ↗

December 24, 2025